356560-76-4

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 17 carbon (C) atoms, 15 hydrogen (H) atoms, 1 nitrogen (N) atom, and 4 oxygen (O) atoms.

Explanation

The compound's structure consists of two main parts a benzo[d][1,3]dioxole ring, which is a fused ring system containing oxygen atoms, and a 6-methylpyridin-2-yl group, which is a pyridine ring with a methyl group at the 6th position. These two groups are connected to a central ethane-1,2-dione moiety, which is a carbonyl-containing molecule.

Explanation

Due to its unique structure and potential biological activities, 1-(benzo[d][1,3]dioxol-5-yl)-2-(6-Methylpyridin-2-yl)ethane-1,2-dione may have applications in the pharmaceutical industry as a drug candidate. It could be used in the development of new medications for various conditions.

Explanation

Additional research is necessary to fully understand the compound's potential uses, effects, and mechanisms of action. This will help determine its suitability as a drug candidate and guide the development of new medications.

Explanation

The specific biological activities of 1-(benzo[d][1,3]dioxol-5-yl)-2-(6-Methylpyridin-2-yl)ethane-1,2-dione are not yet known, as further research is required to explore its potential interactions with biological systems and its effects on various conditions.

Explanation

The chemical properties of 1-(benzo[d][1,3]dioxol-5-yl)-2-(6-Methylpyridin-2-yl)ethane-1,2-dione, such as solubility, stability, and reactivity, are not yet known and would require further investigation to determine.

Explanation

The material does not provide information on the synthesis or preparation of 1-(benzo[d][1,3]dioxol-5-yl)-2-(6-Methylpyridin-2-yl)ethane-1,2-dione. Further research or literature review would be needed to understand the methods used to synthesize 1-(benzo[d][1,3]dioxol-5-yl)-2-(6-Methylpyridin-2-yl)ethane-1,2-dione.

Explanation

The safety and toxicity profiles of 1-(benzo[d][1,3]dioxol-5-yl)-2-(6-Methylpyridin-2-yl)ethane-1,2-dione are not yet known, as further research is required to evaluate its potential side effects and risks associated with its use.

Structure

Benzo[d][1,3]dioxole ring and a 6-methylpyridin-2-yl group attached to a central ethane-1,2-dione moiety

Potential drug candidate

Pharmaceutical applications

Research needed

Further investigation required

Biological activities

Unknown at this stage

Chemical properties

Unknown at this stage

Synthesis

Not provided in the material

Safety and toxicity

Unknown at this stage

Upstream product

• 356560-89-9 1-(benzo[1,3]dioxol-5-yl)-2-(6-methylpyridin-2-yl)ethanone 
• 326-56-7 methyl 3,4-methylenedioxybenzoate 
• 108-48-5 2,6-dimethylpyridine 

Downstream Products

• 943515-19-3 1-allyl-2-[1-allyl-4-(tert-butyl-dimethyl-silanyloxy)-cyclohexyl]-4-(6-methyl-pyridin-2-yl)-5-benzo[1,3]dioxol-5-yl-1H-imidazole 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-β type 1 receptor kinase inhibitors

A series of 4(5)-(6-alkylpyridin-2-yl)imidazoles 13a-p, 17a, and 17b have been synthesized and evaluated for ALK5 inhibitory activity in an enzyme assay and in cell-based luciferase reporter assays. The quinoxalinyl analogue 13e inhibited ALK5 phosphoryla

2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors

Compounds of the formula: wherein R1, R2, R3, A1 and A2 are as defined herein, which are used advantageously in inhibiting the TGF-β and/or activin signaling pathway in mammals.

Pyridinylimidazoles

Compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1, R2 and R3 represent various functional groups, and one of X1 and X2 is N and the other is NR10; and their